SLC5A2 and acute kidney injury: Beyond the outcomes assessed in our analysis, studies have also demonstrated that SGLT2 inhibitors are associated with a reduction in the risk of acute kidney injury as well as renal function decline and progression to end‐stage kidney disease, indicating cardiorenal benefits.18, 33